尿中のビスフェノールA濃度と,子供や青少年における肥満の罹患率との関連
Leonardo Trasande1, Teresa M Attina, Jan Blustein
1Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA. leonardo.trasande@nyumc.org
JAMA
|September 20, 2012
まとめ
尿中のビスフェノールA (BPA) 濃度の上昇は,子供や青少年における肥満の罹患率の増加と関連しています. この研究は,子供の肥満に寄与する潜在的な環境要因を示唆し,BPA暴露と体量に関するさらなる調査を正当化しています.
科学分野:
- 環境の健康 環境の健康
- 小児内分泌学 小児内分泌学
- 公衆衛生は公衆衛生である.
背景:
- ビスフェノールA (BPA) は,成人の健康問題に関連した消費製品に含まれる化学物質です.
- BPA曝露と小児肥満を関連付ける証拠は限られている.
- この研究は,BPAと子供の体量との関連を調査しています.
研究 の 目的:
- 尿中のBPA濃度と子供のボディマス指数 (BMI) の関連性を調べる.
- BPAの曝露が小児集団における肥満の危険因子であるかどうかを判断する.
主な方法:
- 2003~2008年の全国保健栄養調査から2838人の子供と青少年 (6~19歳) の横断分析.
- 尿中のBPA濃度が測定され,BMIは参加者を過体重または肥満に分類するために使用されました.
- 様々な人口,生活様式,環境要因を制御した統計分析.
主要な成果:
- 尿中のBPAの最低四分の一の子供たちは,より高い四分の一の子供と比較して,肥満の有意に低い罹患率を持っていた.
- BMI zスコアでも同様のパターンが観察されました.
- この関連性は白人の子どもでは有意であったが,黒人やヒスパニック系の子どもでは有意ではなかった.
結論:
- 尿中のBPA濃度は,子どもと青年の肥満と有意に関連しています.
- この研究結果から,BPAが子供の肥満に起因する可能性があることが示唆されています.
- 食事による摂取と脂肪組織貯蔵を考慮して,メカニズムを理解するためにさらなる研究が必要である.
関連する概念動画
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Bulimia Nervosa
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...


